US Patent

US11931459 — Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions

Method of Use · Assigned to Pacira Pharmaceuticals Inc · Expires 2042-03-17 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating pain in pediatric patients using sustained-release liposomal anesthetic compositions.

USPTO Abstract

In some embodiments provided herein is a method of treating pain, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3840`	—	Bupivacaine Hydrochloride And Epinephrine
`U-3839`	—	Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number: US11931459
Jurisdiction: US
Classification: Method of Use
Expires: 2042-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Pacira Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.